Home LiteratureArticle Details
PMID: 25432147 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy.

Cancer immunology, immunotherapy : CII ·Vol. 64 ·No. 1 ·2015-01-00 ·Pages 1-13

Messmer MN, Netherby CS, Banik D, Abrams SI

Abstract

Immune function relies on an appropriate balance of the lymphoid and myeloid responses. In the case of neoplasia, this balance is readily perturbed by the dramatic expansion of immature or dysfunctional myeloid cells accompanied by a reciprocal decline in the quantity/quality of the lymphoid response. In this review, we seek to: (1) define the nature of the atypical myelopoiesis observed in cancer patients and the impact of this perturbation on clinical outcomes; (2) examine the potential mechanisms underlying these clinical manifestations; and (3) explore potential strategies to restore normal myeloid cell differentiation to improve activation of the host antitumor immune response. We posit that fundamental alterations in myeloid homeostasis triggered by the neoplastic process represent critical checkpoints that govern therapeutic efficacy, as well as offer novel cellular-based biomarkers for tracking changes in disease status or relapse.

MeSH Terms
Animals Humans Immunotherapy Myeloid Cells/immunology,pathology Neoplasms/immunology,pathology,therapy Tumor Escape/immunology
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Messmer Michelle N
Department of Immunology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
Netherby Colleen S
Banik Debarati
Abrams Scott I
References (125)
125 references, click to expand
  1. Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response.
    Nat Rev Immunol. 2011 Oct;11(10):685-92 PMID: 21904387
  2. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
    PLoS One. 2014;9(2):e87705 PMID: 24498358
  3. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.
    J Clin Oncol. 2007 Jun 20;25(18):2546-53 PMID: 17577033
  4. Paraneoplastic granulocyte colony-stimulating factor secretion in soft tissue sarcoma mimicking myeloproliferative neoplasia: a case report.
    BMC Res Notes. 2014;7:313 PMID: 24885681
  5. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.
    Cancer Immunol Immunother. 2009 Jan;58(1):49-59 PMID: 18446337
  6. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells.
    Cancer Immunol Immunother. 2008 Oct;57(10):1493-504 PMID: 18322683
  7. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model.
    Br J Cancer. 2005 Aug 8;93(3):273-8 PMID: 16052222
  8. Increased circulating Lin(-/low) CD33(+) HLA-DR(-) myeloid-derived suppressor cells in hepatocellular carcinoma patients.
    Hepatol Res. 2014 Jun;44(6):639-50 PMID: 23701406
  9. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.
    Clin Cancer Res. 2008 Dec 15;14(24):8270-8 PMID: 19088044
  10. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.
    J Immunotoxicol. 2014 Oct;11(4):311-8 PMID: 24495309
  11. Induction of immunoregulatory CD271+ cells by metastatic tumor cells that express human endogenous retrovirus H.
    Cancer Res. 2014 Mar 1;74(5):1361-70 PMID: 24590808
  12. Identification of IRF-8 and IRF-1 target genes in activated macrophages.
    Mol Immunol. 2007 Jan;44(4):338-46 PMID: 16597464
  13. Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: profile comparison.
    Int J Urol. 2013 Oct;20(10):971-8 PMID: 23421558
  14. Regulation of IFN-gamma-induced nuclear expression of IFN consensus sequence binding protein in murine peritoneal macrophages.
    J Immunol. 1994 Mar 1;152(5):2270-8 PMID: 8133040
  15. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor.
    Clin Cancer Res. 1995 Jan;1(1):95-103 PMID: 9815891
  16. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.
    PLoS One. 2013;8(2):e57114 PMID: 23437326
  17. Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease.
    Mol Immunol. 2014 Apr;58(2):182-6 PMID: 24370793
  18. Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction.
    J Exp Med. 1997 Nov 3;186(9):1523-34 PMID: 9348310
  19. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.
    J Immunol. 2009 May 15;182(10):6562-8 PMID: 19414811
  20. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45 PMID: 19572148
  21. Tumor-induced immune dysfunctions caused by myeloid suppressor cells.
    J Immunother. 2001 Nov-Dec;24(6):431-46 PMID: 11759067
  22. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia.
    PLoS One. 2013;8(1):e55818 PMID: 23383287
  23. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins.
    J Immunol. 2013 Jan 15;190(2):794-804 PMID: 23248262
  24. Cutting edge: IFN consensus sequence binding protein/IFN regulatory factor 8 drives the development of type I IFN-producing plasmacytoid dendritic cells.
    J Immunol. 2003 Feb 1;170(3):1131-5 PMID: 12538667
  25. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer.
    J Leukoc Biol. 2013 Apr;93(4):633-7 PMID: 23341539
  26. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties.
    J Leukoc Biol. 2011 Feb;89(2):311-7 PMID: 21106641
  27. Identification of target genes and a unique cis element regulated by IRF-8 in developing macrophages.
    Blood. 2005 Sep 15;106(6):1938-47 PMID: 15947094
  28. Myeloid-derived suppressor cell heterogeneity in human cancers.
    Ann N Y Acad Sci. 2014 Jun;1319:47-65 PMID: 24965257
  29. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.
    J Immunol. 2013 Apr 1;190(7):3783-97 PMID: 23440412
  30. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer.
    Blood. 2013 Aug 15;122(7):1105-13 PMID: 23757729
  31. IRF-8/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways.
    J Biol Chem. 2006 Apr 14;281(15):10073-80 PMID: 16484229
  32. CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma.
    Cancer Immunol Immunother. 2014 Nov;63(11):1213-27 PMID: 25143233
  33. Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck.
    Cancer Sci. 2012 Jun;103(6):976-83 PMID: 22360618
  34. ICSBP is critically involved in the normal development and trafficking of Langerhans cells and dermal dendritic cells.
    Blood. 2004 Mar 15;103(6):2221-8 PMID: 14615368
  35. Minimal changes in the systemic immune response after nephrectomy of localized renal masses.
    Urol Oncol. 2014 Jul;32(5):589-600 PMID: 24768357
  36. Transcriptional regulation of granulocyte and monocyte development.
    Oncogene. 2002 May 13;21(21):3377-90 PMID: 12032776
  37. Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients.
    J Immunother. 2014 Jan;37(1):43-50 PMID: 24316555
  38. Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I.
    Clin Cancer Res. 2011 Nov 15;17(22):6992-7002 PMID: 21948231
  39. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism.
    PLoS One. 2011;6(11):e27690 PMID: 22110722
  40. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.
    Clin Cancer Res. 2014 Mar 15;20(6):1601-9 PMID: 24323899
  41. Chemoimmunotherapy: reengineering tumor immunity.
    Cancer Immunol Immunother. 2013 Feb;62(2):203-16 PMID: 23389507
  42. Coordinated regulation of myeloid cells by tumours.
    Nat Rev Immunol. 2012 Apr;12(4):253-68 PMID: 22437938
  43. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.
    Am J Respir Crit Care Med. 2012 Nov 15;186(10):1025-36 PMID: 22955317
  44. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.
    Cancer Cell. 2012 Jun 12;21(6):822-35 PMID: 22698406
  45. ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells.
    J Exp Med. 2002 Dec 2;196(11):1415-25 PMID: 12461077
  46. The hallmarks of cancer.
    Cell. 2000 Jan 7;100(1):57-70 PMID: 10647931
  47. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.
    J Immunol. 2001 Jan 1;166(1):678-89 PMID: 11123353
  48. Immunologic correlates of the abscopal effect in a patient with melanoma.
    N Engl J Med. 2012 Mar 8;366(10):925-31 PMID: 22397654
  49. A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
    J Immunother. 2014 Apr;37(3):180-6 PMID: 24598448
  50. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
    Nat Med. 2012 Aug;18(8):1254-61 PMID: 22842478
  51. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  52. The genomic structure of the murine ICSBP gene reveals the presence of the gamma interferon-responsive element, to which an ISGF3 alpha subunit (or similar) molecule binds.
    Mol Cell Biol. 1993 Jul;13(7):3951-63 PMID: 8321202
  53. Myeloid-derived suppressor cells as regulators of the immune system.
    Nat Rev Immunol. 2009 Mar;9(3):162-74 PMID: 19197294
  54. Myeloid lineage commitment from the hematopoietic stem cell.
    Immunity. 2007 Jun;26(6):726-40 PMID: 17582345
  55. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.
    Cancer Immunol Immunother. 2014 Nov;63(11):1177-87 PMID: 25085000
  56. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma.
    J Clin Oncol. 2006 May 1;24(13):1997-2005 PMID: 16648500
  57. Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome.
    Lung Cancer. 2013 Jul;81(1):130-7 PMID: 23540719
  58. Infiltration of alternatively activated macrophages in cancer tissue is associated with MDSC and Th2 polarization in patients with esophageal cancer.
    PLoS One. 2014;9(8):e104453 PMID: 25144454
  59. Leukocytosis in non hematological malignancies--a possible tumor-associated marker.
    J Cancer Res Clin Oncol. 1986;111(1):54-8 PMID: 3949851
  60. An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes.
    Proc Natl Acad Sci U S A. 1990 May;87(10):3743-7 PMID: 2111015
  61. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice.
    Nat Med. 2014 Jun;20(6):676-81 PMID: 24859530
  62. Altered development and cytokine responses of myeloid progenitors in the absence of transcription factor, interferon consensus sequence binding protein.
    Blood. 1999 Dec 1;94(11):3764-71 PMID: 10572090
  63. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.
    Cancer Immunol Immunother. 2014 Feb;63(2):175-83 PMID: 24292263
  64. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models.
    Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6742-7 PMID: 19346489
  65. Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients.
    Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4221-6 PMID: 24591638
  66. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias.
    Blood. 1998 Jan 1;91(1):22-9 PMID: 9414265
  67. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
    Exp Dermatol. 2014 Mar;23(3):202-4 PMID: 24495013
  68. Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.
    PLoS One. 2014;9(7):e101848 PMID: 25014230
  69. The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8.
    Immunity. 2007 Aug;27(2):228-39 PMID: 17702615
  70. Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression.
    J Exp Med. 1997 Nov 3;186(9):1535-46 PMID: 9348311
  71. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.
    Immunity. 2010 Jun 25;32(6):790-802 PMID: 20605485
  72. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.
    Semin Cancer Biol. 2012 Aug;22(4):275-81 PMID: 22313874
  73. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years.
    Cancer. 2000 Aug 1;89(3):523-33 PMID: 10931451
  74. Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancer.
    PLoS One. 2013;8(5):e65121 PMID: 23717691
  75. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment.
    Immunity. 2006 Jun;24(6):801-12 PMID: 16782035
  76. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.
    Neuro Oncol. 2011 Jun;13(6):591-9 PMID: 21636707
  77. Prognostic impact of monocyte count at presentation in mantle cell lymphoma.
    Br J Haematol. 2013 Aug;162(4):465-73 PMID: 23808798
  78. ICSBP/IRF-8: its regulatory roles in the development of myeloid cells.
    J Interferon Cytokine Res. 2002 Jan;22(1):145-52 PMID: 11846985
  79. Transcriptional regulation in myelopoiesis: Hematopoietic fate choice, myeloid differentiation, and leukemogenesis.
    Exp Hematol. 2005 Feb;33(2):131-43 PMID: 15676205
  80. Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients.
    Lung Cancer. 2013 Sep;81(3):468-74 PMID: 23850196
  81. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.
    J Immunother. 2012 Nov-Dec;35(9):702-10 PMID: 23090079
  82. Increased IL-17 production correlates with immunosuppression involving myeloid-derived suppressor cells and nutritional impairment in patients with various gastrointestinal cancers.
    Mol Clin Oncol. 2013 Jul;1(4):675-679 PMID: 24649227
  83. Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments.
    EMBO J. 1998 Apr 15;17(8):2319-33 PMID: 9545244
  84. Overview of use of G-CSF and GM-CSF in the treatment of acute radiation injury.
    Health Phys. 2014 Jun;106(6):699-703 PMID: 24776902
  85. Inhibition of monocytic differentiation by phosphorylation-deficient Stat1 is associated with impaired expression of Stat2, ICSBP/IRF8 and C/EBPepsilon.
    Scand J Immunol. 2006 Sep;64(3):271-9 PMID: 16918696
  86. The significant increase and dynamic changes of the myeloid-derived suppressor cells percentage with chemotherapy in advanced NSCLC patients.
    Clin Transl Oncol. 2014 Jul;16(7):616-22 PMID: 24193866
  87. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
    J Cancer Res Clin Oncol. 2012 Dec;138(12):2009-16 PMID: 22772951
  88. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma.
    J Immunother. 2010 Oct;33(8):817-27 PMID: 20842055
  89. Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses.
    Front Immunol. 2014 Apr 04;5:147 PMID: 24772111
  90. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients.
    J Immunol Res. 2014;2014:879897 PMID: 24741628
  91. Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC.
    J Transl Med. 2013;11:16 PMID: 23320561
  92. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.
    Cancer Immunol Immunother. 2014 Apr;63(4):407-18 PMID: 24514956
  93. Immunological dysregulation in multiple myeloma microenvironment.
    Biomed Res Int. 2014;2014:198539 PMID: 25013764
  94. IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity.
    J Immunol. 2005 Mar 1;174(5):2573-81 PMID: 15728463
  95. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.
    Cancer Res. 2010 Jun 1;70(11):4335-45 PMID: 20484028
  96. Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer.
    J Cancer Res Clin Oncol. 2009 Dec;135(12):1783-90 PMID: 19551407
  97. Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects.
    PLoS One. 2013;8(10):e76115 PMID: 24146823
  98. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis.
    J Clin Invest. 2013 Oct;123(10):4464-78 PMID: 24091328
  99. An IFN-gamma-inducible transcription factor, IFN consensus sequence binding protein (ICSBP), stimulates IL-12 p40 expression in macrophages.
    J Immunol. 2000 Jul 1;165(1):271-9 PMID: 10861061
  100. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.
    Cancer Immunol Immunother. 2013 Sep;62(9):1439-51 PMID: 23760662
  101. The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes.
    Immunobiology. 2014 Feb;219(2):158-65 PMID: 24091277
  102. Tumor-derived cytokines dysregulate macrophage interferon-gamma responsiveness and interferon regulatory factor-8 expression.
    Exp Biol Med (Maywood). 2003 Mar;228(3):270-7 PMID: 12626771
  103. History of myeloid-derived suppressor cells.
    Nat Rev Cancer. 2013 Oct;13(10):739-52 PMID: 24060865
  104. Helper T-cell identity and evolution of differential transcriptomes and epigenomes.
    Immunol Rev. 2013 Mar;252(1):24-40 PMID: 23405893
  105. Hematopoietic cytokines, transcription factors and lineage commitment.
    Oncogene. 2002 May 13;21(21):3295-313 PMID: 12032771
  106. IRF8 mutations and human dendritic-cell immunodeficiency.
    N Engl J Med. 2011 Jul 14;365(2):127-38 PMID: 21524210
  107. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients.
    J Clin Invest. 2013 Apr;123(4):1580-9 PMID: 23454751
  108. The growing family of interferon regulatory factors.
    Cytokine Growth Factor Rev. 1997 Dec;8(4):293-312 PMID: 9620643
  109. Breakthrough of the year 2013. Cancer immunotherapy.
    Science. 2013 Dec 20;342(6165):1432-3 PMID: 24357284
  110. Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer.
    Oncol Rep. 2012 Aug;28(2):453-8 PMID: 22614133
  111. Mechanisms and functional significance of tumour-induced dendritic-cell defects.
    Nat Rev Immunol. 2004 Dec;4(12):941-52 PMID: 15573129
  112. The role of the interferon regulatory factor (IRF) family in dendritic cell development and function.
    Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):503-10 PMID: 17702640
  113. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
    Gastroenterology. 2008 Jul;135(1):234-43 PMID: 18485901
  114. Interferon regulatory factor 8 regulates RANTES gene transcription in cooperation with interferon regulatory factor-1, NF-kappaB, and PU.1.
    J Biol Chem. 2006 Jul 14;281(28):19188-95 PMID: 16707500
  115. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
    Cancer Immunol Immunother. 2014 Mar;63(3):247-57 PMID: 24357148
  116. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene.
    Cell. 1996 Oct 18;87(2):307-17 PMID: 8861914
  117. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors.
    Immunity. 2014 Sep 18;41(3):389-401 PMID: 25238096
  118. Cancer as an overhealing wound: an old hypothesis revisited.
    Nat Rev Mol Cell Biol. 2008 Aug;9(8):628-38 PMID: 18628784
  119. Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes.
    J Biol Chem. 1992 Dec 15;267(35):25589-96 PMID: 1460054
  120. Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis.
    J Exp Med. 1997 Mar 3;185(5):921-31 PMID: 9120398
  121. γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer.
    Immunity. 2014 May 15;40(5):785-800 PMID: 24816404
  122. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.
    J Immunother Cancer. 2014 May 13;2:11 PMID: 24971166
  123. Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy.
    Cancer Immunol Immunother. 2014 Jan;63(1):59-65 PMID: 24129765
  124. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.
    Cancer Immunol Immunother. 2013 May;62(5):909-18 PMID: 23589106
  125. The IRF family transcription factors in immunity and oncogenesis.
    Annu Rev Immunol. 2008;26:535-84 PMID: 18303999
Article Info
Journal
Cancer immunology, immunotherapy : CII
Abbr.
Cancer Immunol Immunother
ISSN
1432-0851
DOI
10.1007/s00262-014-1639-3
Published
2015-01-00
Epub
2014-00-29
Pages
1-13
Language
English
Region
Germany
NLM ID
8605732
PMCID
PMC4282948
Subset
IM
Grants
NCI NIH HHS · R01 CA140622 · United States
NCI NIH HHS · T32 CA085183 · United States
NCI NIH HHS · R01CA140622 · United States
NCI NIH HHS · T32CA085183 · United States
External Links
PubMed source DOI: 10.1007/s00262-014-1639-3 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2